Nerac

Information That Drives Innovation

We’re here to help with your research needs
+1 860 872 7000
Customer Access
  • Home
  • What We Do
    • Innovation Insights and Consulting Practice
    • Regulatory
    • Medical Device and Life Sciences
    • Technology Scouting and Innovation
    • Market Research
    • Intellectual Property
    • Commercialization Services for TTOs and Start-Ups
    • Critical Updates
  • Who We Serve
  • How to Engage
  • Why Nerac?
  • Meet our Team
    • Leadership Team
    • Our Analysts
    • Our Partners
  • Nerac Insights and Publications
    • Articles
    • Case Studies
    • Press Room
    • Videos
    • Webcasts
    • White Papers
  • Contact Us
You are here: Home / Nerac Insights / Articles / Donna Mitchell-Magaldi / In Vitro Diagnostics – Upcoming Regulatory Developments in the U.S. and European Union: Are You Ready for the Transition?

In Vitro Diagnostics – Upcoming Regulatory Developments in the U.S. and European Union: Are You Ready for the Transition?

Facebook1
Google+0
LinkedIn20
Twitter0

Join Nerac Regulatory analysts Roz Sweeney, Ph.D. and Donna Mitchell-Magaldi for this powerful discussion designed to give you the insights and information you need on the new EU/FDA regulatory proposals/guidances and how they will be implemented by the agencies!!

It is imperative that IVD manufacturers prepare for upcoming/new regulatory changes in both the EU and US. CLIA labs in the US need to be ready for expected regulatory changes, with enforcement expected to begin around Q4, 2015.

EU Changes
In this portion of the webinar, we will discuss the most up to date (straight from RAPS Conference) information concerning the new EU classification system and what this means in terms of the amount of regulatory oversight for each, including:

  • Which IVDs will fall into which category?
  • When do auditors plan on implementing the system?
  • How much time will IVD companies have to comply?
  • What are the compliance requirements, such as product sampling, new clinical data requirements, unannounced audits and more!

FDA Changes
This portion of the webinar will cover the new draft guidance on laboratory developed tests (LDTs) for CLIA labs, including:

  • Timeframe for implementation by the agency
  • Which assays will likely be excluded from the law
  • Which assays will be considered high, medium, and low risk
  • New requirements for LDTs

Finally, we will discuss FDA guidance on assay migration studies and RUO/IUO assays.

Did you miss the webcast? You can listen and watch it here!

Related Posts

  • Webcast: In Vitro Diagnostics - Upcoming Regulatory Developments in the U.S. and European Union: Are You Ready for the Transition?
    61
    Did you miss our recent webcast "In Vitro Diagnostics - Upcoming Regulatory Developments in the US and EU: Are You Ready for the Transition?" You can listen and watch it here.
    Tags: webinar, diagnostics, vitro, regulatory
  • FDA’s Proposed Regulatory Changes to Laboratory-Developed Tests (LDTs)
    57
    By Roz Sweeney, Ph.D., Nerac Analyst Originally Published: November 17th, 2014 Introduction The FDA recently issued updated draft guidance for proposed regulatory changes affecting laboratory developed tests (LDTs). Laboratory developed tests (or LDTs) are traditionally IVDs developed and used by CLIA labs for treating or testing patients within that lab’s associated healthcare facility. They have…
    Tags: ldts, fda, regulatory, labs, clinical, nerac, roz, changes, analyst, ph.d
  • Bringing Functional Foods to Market: FDA’s Regulatory Mandate Drives the Process
    40
    Originally published February, 2011 Introduction Bringing a new functional food product to market is a potentially complex process with many decision points driven by the US Food and Drug Administration’s (FDA) regulatory mandate. There is no single definition for functional foods, also known as nutraceuticals. They may encompass a range of products and uses, including…
    Tags: product, regulatory, fda
  • Case Studies
  • White Papers
  • Webcasts
  • Articles
    • Nerac Strategist
    • Energy
    • Food & Nutrition
    • Intellectual Property
    • Regulatory
    • Technology & Innovation
    • Medical Device & Healthcare
    • Pharmaceutical
    • Engineering
    • Market Research
    • Critical Alerts
    • Chemistry/Advanced Materials
  • Press Room

Click here to learn more about….

3d printing advanced materials aerospace Ask Kevin Videos biotech CFDA clinical literature evaluations commercialization strategies competitive intelligence conflict minerals Disruptive Technologies emerging markets energy EU MDR FDA food Industry 4.0 innovation Inspiring Next intellectual property intellectual property strategies IP market analysis market research medical device medical devices nerac Nerac client questions Nerac Strategist notified body audit open innovation Order 650 patenting strategies patent landscape pharmaceutical Post-Market Surveillance R&D regulatory regulatory compliance Robert Beinstein Rosemarie Szostak specialty chemicals Sustainable Development Goals technology scouting XcellR8
  • Facebook
  • Google+
  • Linkedin
  • RSS
  • Twitter
  • YouTube
  • Career Opportunities

Copyright © 2021 Nerac · One Technology Drive · Tolland, CT 06084 · 1.860.872.7000

Sign Up for the Nerac Strategist

Like what you see? Sign up here to receive the Nerac Strategist newsletter, a compilation of analyst insights on rapidly developing industry issues, compliance challenges and commercial opportunities!
  • This field is for validation purposes and should be left unchanged.